Contractile effects of albiglutide in the human and mouse atrium
-
By
-
Joachim Neumann
-
Milena Jarikova
-
Uwe Kirchhefer
-
Britt Hofmann
-
Ulrich Gergs
-
July 3, 2026
-
Clinical Scorecard: Inotropic Effects of Albiglutide on Human and Murine Atrial Tissue
At a Glance
| Category | Detail |
|---|
| Condition | Type 2 Diabetes |
| Key Mechanisms | Positive inotropic effect via GLP-1R stimulation and cAMP-dependent phosphorylation. |
| Target Population | Adult patients with severe coronary heart disease. |
| Care Setting | Clinical research in cardiac tissue preparations. |
Key Highlights
- Albiglutide shows a time- and concentration-dependent positive inotropic effect in human atrial preparations.
- The effect is enhanced by cilostamide and attenuated by GLP-1R antagonist exendin(9-39).
- Albiglutide does not increase contractility in murine atrial preparations.
- It acts as a partial GLP-1R agonist, potentially leading to fewer side effects than full agonists.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Patients with type 2 diabetes and cardiovascular morbidities.
Albiglutide may provide inotropic support without significant adverse effects compared to full GLP-1R agonists.
Clinical Best Practices
- Consider the use of albiglutide in patients with type 2 diabetes and heart disease.
- Monitor cardiac contractility when using GLP-1R agonists.
Related Resources & Content
